Bavarian Nordic A/S (BVNRY)
USD 8.07
(3.2%)
USD 8.07
(3.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.1 Billion DKK | 70.66% |
| 2022 | 1.77 Billion DKK | 100.49% |
| 2021 | 883.86 Million DKK | 218.28% |
| 2020 | 277.7 Million DKK | -56.35% |
| 2019 | 636.17 Million DKK | 6.03% |
| 2018 | 599.98 Million DKK | -17.4% |
| 2017 | 726.34 Million DKK | 7.46% |
| 2016 | 675.94 Million DKK | 11.94% |
| 2015 | 603.86 Million DKK | -14.35% |
| 2014 | 705.05 Million DKK | 1.54% |
| 2013 | 694.38 Million DKK | 29.85% |
| 2012 | 534.76 Million DKK | 24.81% |
| 2011 | 428.47 Million DKK | 24.67% |
| 2010 | 343.69 Million DKK | 24.59% |
| 2009 | 275.86 Million DKK | 17.13% |
| 2008 | 235.53 Million DKK | -31.13% |
| 2007 | 342.01 Million DKK | 27.49% |
| 2006 | 268.26 Million DKK | 14.09% |
| 2005 | 235.14 Million DKK | 32.96% |
| 2004 | 176.85 Million DKK | 71.02% |
| 2003 | 103.41 Million DKK | 13.3% |
| 2002 | 91.27 Million DKK | -2.36% |
| 2001 | 93.48 Million DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 454.05 Million DKK | 15.2% |
| 2024 Q1 | 394.13 Million DKK | -43.84% |
| 2023 FY | 3.02 Billion DKK | 70.66% |
| 2023 Q4 | 701.82 Million DKK | -40.93% |
| 2023 Q1 | 453.9 Million DKK | -38.43% |
| 2023 Q3 | 1.18 Billion DKK | 57.01% |
| 2023 Q2 | 756.68 Million DKK | 66.71% |
| 2022 Q3 | 491.84 Million DKK | 52.27% |
| 2022 Q4 | 737.21 Million DKK | 49.89% |
| 2022 Q1 | 219.97 Million DKK | -3.9% |
| 2022 Q2 | 323.01 Million DKK | 46.84% |
| 2022 FY | 1.77 Billion DKK | 100.49% |
| 2021 Q1 | 245.9 Million DKK | -4.0% |
| 2021 Q3 | 181.72 Million DKK | -20.06% |
| 2021 FY | 883.86 Million DKK | 218.28% |
| 2021 Q4 | 228.89 Million DKK | 25.95% |
| 2021 Q2 | 227.33 Million DKK | -7.55% |
| 2020 Q2 | 207.87 Million DKK | 147.76% |
| 2020 Q1 | -435.26 Million DKK | -333.8% |
| 2020 Q4 | 256.14 Million DKK | 2.89% |
| 2020 FY | 277.7 Million DKK | -56.35% |
| 2020 Q3 | 248.95 Million DKK | 19.76% |
| 2019 Q4 | 186.16 Million DKK | 25.91% |
| 2019 Q1 | 153.58 Million DKK | -6.89% |
| 2019 Q2 | 148.57 Million DKK | -3.27% |
| 2019 FY | 636.17 Million DKK | 6.03% |
| 2019 Q3 | 147.85 Million DKK | -0.48% |
| 2018 Q2 | 147.7 Million DKK | -10.51% |
| 2018 Q4 | 164.94 Million DKK | 34.9% |
| 2018 Q1 | 165.05 Million DKK | -19.2% |
| 2018 FY | 599.98 Million DKK | -17.4% |
| 2018 Q3 | 122.27 Million DKK | -17.22% |
| 2017 Q3 | 203.52 Million DKK | 21.25% |
| 2017 Q4 | 204.28 Million DKK | 0.37% |
| 2017 FY | 726.34 Million DKK | 7.46% |
| 2017 Q1 | 150.68 Million DKK | -22.68% |
| 2017 Q2 | 167.85 Million DKK | 11.4% |
| 2016 Q1 | 156.4 Million DKK | 5.13% |
| 2016 Q2 | 142.28 Million DKK | -9.03% |
| 2016 FY | 675.94 Million DKK | 11.94% |
| 2016 Q3 | 182.36 Million DKK | 28.17% |
| 2016 Q4 | 194.88 Million DKK | 6.86% |
| 2015 FY | 603.86 Million DKK | -14.35% |
| 2015 Q4 | 148.77 Million DKK | 25.99% |
| 2015 Q3 | 118.08 Million DKK | -23.37% |
| 2015 Q2 | 154.1 Million DKK | -15.75% |
| 2015 Q1 | 182.9 Million DKK | -22.58% |
| 2014 Q3 | 177.7 Million DKK | 16.14% |
| 2014 Q4 | 236.25 Million DKK | 32.95% |
| 2014 FY | 705.05 Million DKK | 1.54% |
| 2014 Q1 | 138.1 Million DKK | -13.79% |
| 2014 Q2 | 153 Million DKK | 10.79% |
| 2013 Q2 | 259.9 Million DKK | 112.86% |
| 2013 Q3 | 152.2 Million DKK | -41.44% |
| 2013 Q4 | 160.18 Million DKK | 5.24% |
| 2013 FY | 694.38 Million DKK | 29.85% |
| 2013 Q1 | 122.1 Million DKK | -34.8% |
| 2012 Q3 | 124.7 Million DKK | 7.04% |
| 2012 Q2 | 116.5 Million DKK | 9.6% |
| 2012 Q4 | 187.26 Million DKK | 50.17% |
| 2012 FY | 534.76 Million DKK | 24.81% |
| 2012 Q1 | 106.3 Million DKK | -20.54% |
| 2011 Q4 | 133.77 Million DKK | 31.03% |
| 2011 Q3 | 102.1 Million DKK | 3.03% |
| 2011 FY | 428.47 Million DKK | 24.67% |
| 2011 Q2 | 99.1 Million DKK | 5.99% |
| 2011 Q1 | 93.5 Million DKK | -15.53% |
| 2010 Q3 | 81.9 Million DKK | -2.38% |
| 2010 FY | 343.69 Million DKK | 24.59% |
| 2010 Q4 | 110.69 Million DKK | 35.15% |
| 2010 Q2 | 83.9 Million DKK | 24.48% |
| 2010 Q1 | 67.4 Million DKK | -36.4% |
| 2009 Q3 | 65.2 Million DKK | -2.98% |
| 2009 Q4 | 105.96 Million DKK | 62.53% |
| 2009 FY | 275.86 Million DKK | 17.13% |
| 2009 Q2 | 67.2 Million DKK | 3.86% |
| 2009 Q1 | 64.7 Million DKK | 0.0% |
| 2008 FY | 235.53 Million DKK | -31.13% |
| 2007 FY | 342.01 Million DKK | 27.49% |
| 2006 FY | 268.26 Million DKK | 14.09% |
| 2005 FY | 235.14 Million DKK | 32.96% |
| 2004 FY | 176.85 Million DKK | 71.02% |
| 2003 FY | 103.41 Million DKK | 13.3% |
| 2002 FY | 91.27 Million DKK | -2.36% |
| 2001 FY | 93.48 Million DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -84989.929% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -231452.725% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -118124.852% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -10411.231% |
| GB Sciences, Inc. | 1.42 Million USD | -218581.05% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -91130.636% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1411392.289% |
| Skye Bioscience, Inc. | 13.54 Million USD | -22829.489% |
| Zenith Capital Corp. | 8.94 Million USD | -34635.368% |
| Agentix Corp. | 1.37 Million USD | -226353.101% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -61509.617% |
| Biomind Labs Inc. | 994.18 Thousand USD | -312356.271% |
| ContraFect Corporation | 56.88 Million USD | -5360.43% |
| CSL Limited | 3.44 Billion USD | 9.934% |
| CytoDyn Inc. | 18.05 Million USD | -17102.259% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -166518.429% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -797296.077% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -5308.05% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -747563.299% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -206730.419% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -336267.121% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -8238.016% |
| SQZ Biotechnologies Company | 85.61 Million USD | -3528.148% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -151526.711% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3479.402% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -106420.359% |
| Mesoblast Limited | 5.9 Million USD | -52532.735% |
| Marizyme, Inc. | 19.23 Million USD | -16045.588% |
| Genus plc | 147.7 Million USD | -2003.171% |
| Pharming Group N.V. | 225.49 Million USD | -1277.609% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -37151.277% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -209967.949% |
| IMV Inc. | 37.7 Million USD | -8137.732% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -111225.683% |
| MultiCell Technologies, Inc. | 567.42 USD | -547457515.17% |
| ONE Bio Corp. | 6.44 Million USD | -48106.643% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -3514.386% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -12468.821% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -176431.388% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -46139.611% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 12425636.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -19302.486% |
| Alpha Cognition Inc. | 9.7 Million USD | -31906.096% |
| Enzolytics Inc. | 2.17 Million USD | -142426.911% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | -102.564% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -297446.36% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -129067.121% |
| Genscript Biotech Corporation | 825.34 Million USD | -276.374% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -63064.68% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1186783.993% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -126416.617% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1811107.575% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -161614.524% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -35283.315% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -70360.765% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -82816.086% |
| Helix BioMedix, Inc. | 1.97 Million USD | -157421.828% |
| EV Biologics, Inc. | 531.96 Thousand USD | -583848.478% |
| Q BioMed Inc. | 3.43 Million USD | -90290.464% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -28485.479% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -3027.332% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -13420.83% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -169176.468% |
| HST Global, Inc. | 140.9 Thousand USD | -2204463.294% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -232512.842% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -276045.114% |
| Halberd Corporation | 74.84 Thousand USD | -4150489.241% |
| Resverlogix Corp. | 12.71 Million USD | -24336.627% |
| Cell Source, Inc. | 4.32 Million USD | -71718.162% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -196586.875% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -42393.459% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -17831161.122% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -125829.671% |
| Kadimastem Ltd | 2.41 Million USD | -128789.612% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -73191.189% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1711547.795% |
| LadRx Corporation | 3.81 Million USD | -81394.08% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -336267.121% |
| Affymax, Inc. | 39.38 Million USD | -7787.026% |
| Itoco Inc. | 919.14 Thousand USD | -337865.257% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -277503.575% |
| Mobile Lads Corp. | 554.54 Thousand USD | -560067.056% |
| International Stem Cell Corporation | 5.27 Million USD | -58833.485% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -81215.824% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -12342003.381% |
| Qrons Inc. | 643.67 Thousand USD | -482499.813% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -218691.485% |
| SYBLEU INC | 160.87 Thousand USD | -1930818.223% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -139207.29% |
| Rebus Holdings, Inc. | 664 Thousand USD | -467728.916% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -170926.251% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5900861.21% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -15269938.834% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -8465.555% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -191889.122% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -422057.685% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -99751.623% |
| Neutra Corp. | 243.82 Thousand USD | -1273942.843% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -17694.489% |
| PureTech Health plc | 144.59 Million USD | -2048.305% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -15060.571% |
| IXICO plc | 4.7 Million USD | -65894.986% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -35211.856% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -2538.163% |
| CSL Limited | 3.89 Billion USD | 20.206% |
| Cellectis S.A. | 97.32 Million USD | -3091.928% |